The New England Journal of Medicine has published a detailed analysis of Genentech’s positive results from the Phase III REGENCY study of Gazyva® (Obinutuzumab) for people with active lupus nephritis ...

Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company ...

Obinutuzumab could reshape the treatment of lupus nephritis, a life-threatening complication of lupus that has long lacked ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

Atherosclerosis cardiovascular disease (ASCVD)-related mortality is higher in patients with lupus nephritis (LN) compared ...

The following is a summary of “Nomogram for predicting proliferative lupus nephritis in patients with low-level proteinuria,” ...

The following is a summary of “Distinct genetic risk loci between biopsy-proven renal and non-renal lupus: a 10-year ...

in proliferative lupus nephritis (LN) patients who discontinued immunosuppressive therapy (IST), as well as the long-term renal outcomes following RR. Methods Retrospective, single-centre study of ...

The effort, dubbed India Pathology Dataset (IPD) project, a collaborative initiative involving academia, hospitals, industry, and govt, aims to digitise tissue biopsy slides ... also compiled a ...

Department of Rheumatology, Research Center of Clinical Medicine, Research Center of Clinical Immunology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong ...

This can cause lupus panniculitis symptoms. If a doctor suspects lupus panniculitis, they will likely recommend a skin biopsy. A deep skin biopsy involves removing a small part of the tissue under ...